- Company
- Cancer immunotherapy are being applied to expand benefits
- by Eo, Yun-Ho Apr 26, 2022 06:11am
- Tecentriq will apply primary therapy benefits for liver and non-small cell lung cancer from May According to related industries, Roche Tecentriq will be applied to liver cancer and non-small cell lung cancer indicators from May as Merck and Pfizer Bavencio (Avelumab) passed the Cancer Drugs Benefit Appraisal Committee. The benefit standard
- Company
- JAKi options added to Dupixent for atopic dermatitis
- by Eo, Yun-Ho Apr 25, 2022 06:07am
- Two new treatment options were added to the field of atopic dermatitis that had only Dupixent as an option. The new options are both JAK inhibitors. The Ministry of Health and Welfare had issued a pre-administrative notice on the ‘Details on the standard and methods for applying long-term care benefits (pharmaceuticals)’ and announced i
- Company
- COVID-19 Tx Lagevrio lands in tertiary hospitals in Korea
- by Eo, Yun-Ho Apr 25, 2022 06:07am
- The oral COVID-19 treatment ‘Lagevrio’ has officially landed for prescriptions at general hospitals in Korea. According to industry sources, MSD Korea’s Lagevrio (molnupiravir) has passed the drug committees of tertiary hospitals including the Seoul National University Hospital in Korea. With the approval, the drug may be prescribed fo
- Company
- Sales of Expectants & antibiotic have increased
- by Chon, Seung-Hyun Apr 25, 2022 06:07am
- Sales in the outpatient prescription market have been rising sharply this year. Sales in the prescription market have been rising as the number of COVID-19 confirmed cases has soared since late last year. The Expectant and antibiotic prescription market, which is used for colds and infectious disease diseases, recovered to the level before the o
- Company
- LDL-C target for cardiovascular dz will be lowered in Korea
- by Apr 25, 2022 06:07am
- The LDL-C target figure for South Korea's ultra-high-risk group for cardiovascular diseases is expected to be lowered to a similar level to global guidelines. The Korean Society of Lipid and Atherosclerosis held the Spring Cardiovascular Integration Academic Conference online and offline at the HICO on the 15th and 16th and unveiled some of t
- Company
- Samsung BioLogics acquired all of its shares in Epis
- by Chon, Seung-Hyun Apr 24, 2022 06:33pm
- Samsung BioLogics will incorporate Samsung Bioepis as a 100% subsidiary and operate a separate management system. Samsung BioLogics announced on the 20th that it has completed the first payment of $1 billion in the acquisition of Epis shares to Biogen. From the day the first payment was completed under the contract between the two companies,
- Company
- Tecentriq, first immunotherapy reimbursed in liver cancer
- by jung, sae-im Apr 22, 2022 06:07am
- Roche’s Tecentriq(atezolizumab) became the first cancer immunotherapy to be approved for reimbursement in liver cancer. Analysts have assessed that it had prepared the footsold to expand its sales with the first expansion in its scope of reimbursement in 3 years since 2019. Tecentriq is continuing its stride to overcome the stronghold of Ke
- Company
- The opinions of the pharmaceutical community vary widely
- by jung, sae-im Apr 22, 2022 06:07am
- Employees of pharmaceutical companies who have entered the era of post-COVID-19 due to the end of social distancing are divided. Various opinions are coming out as it is divided into pharmaceutical companies that maintain telecommuting and pharmaceutical companies that terminate. Pros and cons also followed group meetings such as company dinn
- Company
- Companies are struggling with the form of post-COVID-19 work
- by Apr 20, 2022 06:06am
- As social distancing measures are lifted in two years, changes are also detected in the pharmaceutical industry. However, telecommuting is unlikely to disappear immediately. As more and more conferences attempt online and offline hybridization this year, they are also cautious about overseas business trips. ◆ Maintaining voluntary work
- Company
- Homegrown Rosuzet·K-CAB sell over ₩10 bil a month
- by Chon, Seung-Hyun Apr 20, 2022 06:05am
- New drugs developed by Korean pharmaceutical companies are showing strength in the prescription market. Hanmi Pharmaceutical’s Rosuzet and HK Inno. N’s K-CAB has recorded over &8361;10 billion in monthly sales and made a good start. According to the market research institution UBIST on the 19th, the hyperlipidemia treatment Lipitor record
